CN Patent

CN115484954A — Irak1的有效和选择性不可逆抑制剂

Assigned to Dana Farber Cancer Institute Inc · Expires 2022-12-16 · 3y expired

What this patent protects

本公开涉及作为白介素1(IL‑1)受体相关激酶(IRAK)的不可逆抑制剂的化合物；包含所述化合物的药物组合物；以及治疗或预防激酶介导的病症(包括癌症和其他增殖性疾病)的方法。

USPTO Abstract

本公开涉及作为白介素1(IL‑1)受体相关激酶(IRAK)的不可逆抑制剂的化合物；包含所述化合物的药物组合物；以及治疗或预防激酶介导的病症(包括癌症和其他增殖性疾病)的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN115484954A
Jurisdiction
CN
Classification
—
Expires
2022-12-16
Drug substance claim
No
Drug product claim
No
Assignee
Dana Farber Cancer Institute Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.